TNX-1900 is under clinical development by Tonix Pharmaceuticals Holding and currently in Phase II for Binge Eating Disorder. According to GlobalData, Phase II drugs for Binge Eating Disorder have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TNX-1900’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TNX-1900 overview

Oxytocin (TI-001) is under development for the treatment of chronic migraine, binge eating disorder, social anxiety disorder (SAD), obesity in adults and pediatrics. The drug candidate is an intranasal oxytocin formulation. It acts by targeting oxytocin receptor and CGRP (Calcitonin Gene Related Peptide) . It was also under development for the treatment of trigeminal neuralgia, chronic daily headache (CDH), craniofacial pain, mild traumatic brain injury, binge eating disorder, insulin resistance and obesity.

For a complete picture of TNX-1900’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 17 November 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.